Durvalumab Shows Activity in Patients who Progressed on Platinum-Based Chemo

EC approves Padcev + Keytruda for advanced urothelial cancer

The European Commission approved Padcev (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.

September 06, 2024

Vol.50 No.33

Drugs & Targets

CHMP adopts positive opinion of Keytruda + Padcev for unresectable or metastatic urothelial carcinoma

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Keytruda in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.

August 02, 2024

Vol.50 No.31

Drugs & Targets

European Commission approves Opdivo combination for unresectable or metastatic UC

The European Commission has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.

May 31, 2024

Vol.50 No.22

Drugs & Targets

FDA approves Opdivo + cisplatin + gemcitabine for unresectable or metastatic urothelial carcinoma

FDA approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.

March 08, 2024

Vol.50 No.10

Drugs & Targets

FDA approves Balversa for locally advanced or metastatic urothelial carcinoma

FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy.

January 26, 2024

Vol.50 No.04

In Brief

Fayez Estephan named assistant professor of medicine at GW University Cancer Center

Fayez Estephan was named assistant professor of medicine in the Division of Hematology and Oncology at George Washington University Cancer Center and GW School of Medical and Health Sciences.

November 03, 2023

Vol.49 No.41

Durvalumab Shows Activity in Patients who Progressed on Platinum-Based Chemo

YOU MAY BE INTERESTED IN

EC approves Padcev + Keytruda for advanced urothelial cancer

CHMP adopts positive opinion of Keytruda + Padcev for unresectable or metastatic urothelial carcinoma

European Commission approves Opdivo combination for unresectable or metastatic UC

FDA approves Opdivo + cisplatin + gemcitabine for unresectable or metastatic urothelial carcinoma

FDA approves Balversa for locally advanced or metastatic urothelial carcinoma

Fayez Estephan named assistant professor of medicine at GW University Cancer Center

Renew today!

Subscriber content

Never miss an issue!

Login